JP2007531510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531510A5 JP2007531510A5 JP2006536535A JP2006536535A JP2007531510A5 JP 2007531510 A5 JP2007531510 A5 JP 2007531510A5 JP 2006536535 A JP2006536535 A JP 2006536535A JP 2006536535 A JP2006536535 A JP 2006536535A JP 2007531510 A5 JP2007531510 A5 JP 2007531510A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- vertebrate
- immunomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 241000251468 Actinopterygii Species 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- UAGYHIZGHDGMCY-FNCVBFRFSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-pyrimidin-1-ium-1-yloxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CN=C1 UAGYHIZGHDGMCY-FNCVBFRFSA-N 0.000 claims 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims 1
- NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1H-pyrimidin-2-one Chemical group NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 claims 1
- 206010049460 Abasia Diseases 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 229940104302 Cytosine Drugs 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 230000002009 allergen Effects 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002215 arabinonucleoside Substances 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003835 nucleoside group Chemical class 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 230000001717 pathogenic Effects 0.000 claims 1
- 244000052769 pathogens Species 0.000 claims 1
- 150000002972 pentoses Chemical group 0.000 claims 1
- 239000002718 pyrimidine nucleoside Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
Claims (9)
- イムノマーであって、一緒に結合している2つまたは3つ以上のオリゴヌクレオチド分枝を含み、そして、構造:
5’−NnpYpRpNnp3’−Lm−3’NnpRpYpNn−5’;式中、各Nは、独立してヌクレオシド、ヌクレオシド類似体;アラビノヌクレオシドまたは脱塩基糖から選択され;各pは、独立して天然または修飾インターヌクレオシド連鎖であり;少なくとも1つのYは、シトシン、5−ヒドロキシシトシン、N4−アルキルシトシン、4−チオウラシルまたは他の非天然ピリミジンヌクレオシド、あるいは2−オキソ−7−デアザ−8−メチル−プリンからなる群から選択され、ここで前記塩基が2−オキソ−7−デアザ−8−メチル−プリンである場合には、これは前記塩基の1位を介してペントースの1’位に共有結合しており;少なくとも1つのRは、グアニン、2−アミノ−6−オキソ−7−デアザプリン、2−アミノ−6−チオプリン、6−オキソプリンまたは他の非天然プリンヌクレオシドからなる群から選択され;Lは非ヌクレオチドリンカーであり;各nは、独立して0〜4の数値であり、但し、いずれの分枝も6ヌクレオチドを超えることはなく;mは0〜10の数値であり、そして各Nは、任意にかつ独立に、非ヌクレオチドリンカーと共有結合していてもよい、
を有する、前記イムノマー。 - 請求項1に記載のイムノマーを含む、脊椎動物において免疫反応を調節するための医薬組成物。
- 脊椎動物が、魚類、鳥類および哺乳動物からなる群から選択される、請求項2に記載の医薬組成物。
- 哺乳動物が、ラット、マウス、ネコ、イヌ、ウマ、ウシ、ブタ、ウサギ、非ヒト霊長類およびヒトからなる群から選択される、請求項3に記載の医薬組成物。
- 請求項1に記載のイムノマーを含む、疾患を有する脊椎動物を処置するための医薬組成物。
- 脊椎動物が、魚類、鳥類および哺乳動物からなる群から選択される、請求項5に記載の医薬組成物。
- 哺乳動物が、ラット、マウス、ネコ、イヌ、ウマ、ウシ、ブタ、ウサギ、非ヒト霊長類およびヒトからなる群から選択される、請求項6に記載の医薬組成物。
- 処置されるべき疾患が、癌、自己免疫疾患、気道炎症、喘息、アレルギーおよび病原体により惹起される疾患からなる群から選択される、請求項5に記載の医薬組成物。
- ワクチン、アレルゲン、抗原、抗体、モノクローナル抗体、化学療法剤、抗生剤、脂質、DNAワクチン、およびミョウバンなどの他のアジュバントからなる群から選択される剤をさらに含む、請求項5に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/361,111 US7354907B2 (en) | 2003-02-07 | 2003-02-07 | Short immunomodulatory oligonucleotides |
PCT/US2004/000789 WO2004071468A2 (en) | 2003-02-07 | 2004-01-13 | Short immunomodulatory oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007531510A JP2007531510A (ja) | 2007-11-08 |
JP2007531510A5 true JP2007531510A5 (ja) | 2007-12-20 |
Family
ID=32824138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006536535A Pending JP2007531510A (ja) | 2003-02-07 | 2004-01-13 | 短い免疫調節性オリゴヌクレオチド |
Country Status (8)
Country | Link |
---|---|
US (2) | US7354907B2 (ja) |
EP (1) | EP1594432A4 (ja) |
JP (1) | JP2007531510A (ja) |
KR (1) | KR20050098302A (ja) |
AU (1) | AU2004210625A1 (ja) |
CA (1) | CA2512934A1 (ja) |
MX (1) | MXPA05008360A (ja) |
WO (1) | WO2004071468A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100334228C (zh) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | 嵌合免疫调制化合物及其使用方法 |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
DE10328813B4 (de) * | 2003-06-20 | 2006-04-13 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA-Sequenzen mittels triplexbildender Oligomere |
BRPI0512110A (pt) * | 2004-06-15 | 2007-10-23 | Idera Pharmaceutical Inc | multìmeros de oligonucleotìdeos imunoestimulatórios |
US7498425B2 (en) * | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
WO2011028550A1 (en) * | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Segmented micro rna mimetics |
EP2943251B1 (en) * | 2013-01-08 | 2018-10-10 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
CN106754739A (zh) * | 2016-12-30 | 2017-05-31 | 天津三箭生物技术股份有限公司 | 小鼠抗人p53单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
CN108178698A (zh) * | 2018-03-19 | 2018-06-19 | 联保作物科技有限公司 | 含嘧啶核苷类抗菌素和磷酸氢二钾的复配组合物、农业杀菌剂及其应用 |
EP3950698A4 (en) * | 2019-03-28 | 2023-01-25 | Ajinomoto Co., Inc. | METHOD FOR PRODUCING AN OLIGONUCLEOTIDE HAVING A PHOSPHOROTHIOATE SITE |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5968909A (en) * | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
KR100651294B1 (ko) * | 1999-08-13 | 2006-11-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 누클레오시드의 위치적 변형에 의한 올리고누클레오티드CpG-매개된 면역 자극의 조절 |
EP1252307B1 (en) * | 2000-01-26 | 2008-01-02 | Idera Pharmaceuticals, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
KR100875003B1 (ko) * | 2000-05-01 | 2008-12-19 | 이데라 파마슈티칼즈, 인코포레이티드 | 누클레오시드의 위치 변형에 의한 올리고누클레오티드 CpG 매개성 면역 자극의 조절 |
WO2002008265A2 (en) * | 2000-07-19 | 2002-01-31 | Pharmacia & Upjohn Company | Staphylococcus aureus ribosomal protein s20, corresponding gene and methods for the identification of antibacterial substances |
KR100865706B1 (ko) * | 2000-09-26 | 2008-10-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
US7176296B2 (en) * | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7105495B2 (en) * | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20030129605A1 (en) * | 2001-05-04 | 2003-07-10 | Dong Yu | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages |
CN100334228C (zh) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | 嵌合免疫调制化合物及其使用方法 |
WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
EP1393745A1 (en) * | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
US7569554B2 (en) * | 2003-05-16 | 2009-08-04 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
EP2060269A3 (en) * | 2003-12-08 | 2009-08-19 | Hybridon, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
AU2005216075B2 (en) * | 2004-02-20 | 2011-03-10 | Idera Pharmaceuticals, Inc. | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
US7498425B2 (en) * | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
BRPI0512110A (pt) * | 2004-06-15 | 2007-10-23 | Idera Pharmaceutical Inc | multìmeros de oligonucleotìdeos imunoestimulatórios |
WO2006011160A1 (en) * | 2004-06-28 | 2006-02-02 | Alembic Limited | Process for the preparation of azithromycin monohydrate isopropanol clathrate |
EP1734583A1 (en) * | 2005-06-14 | 2006-12-20 | Photonis-DEP B.V. | Electron bombarded image sensor array device and its manufactoring method |
US20070093439A1 (en) * | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
CA2630118A1 (en) * | 2005-11-07 | 2007-05-18 | Sudhir Agrawal | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
JP2009520502A (ja) * | 2005-12-20 | 2009-05-28 | イデラ ファーマシューティカルズ インコーポレイテッド | Cgジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト |
WO2007075626A2 (en) * | 2005-12-20 | 2007-07-05 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments |
MX2009003398A (es) * | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
CN101610671A (zh) * | 2006-12-12 | 2009-12-23 | 艾德拉药物股份有限公司 | 合成的tlr9激动剂 |
CN101878311A (zh) * | 2007-08-01 | 2010-11-03 | 艾德拉药物股份有限公司 | Tlr9的新型合成性激动剂 |
-
2003
- 2003-02-07 US US10/361,111 patent/US7354907B2/en not_active Expired - Fee Related
-
2004
- 2004-01-13 MX MXPA05008360A patent/MXPA05008360A/es unknown
- 2004-01-13 JP JP2006536535A patent/JP2007531510A/ja active Pending
- 2004-01-13 KR KR1020057014457A patent/KR20050098302A/ko not_active Application Discontinuation
- 2004-01-13 AU AU2004210625A patent/AU2004210625A1/en not_active Abandoned
- 2004-01-13 EP EP04701751A patent/EP1594432A4/en not_active Withdrawn
- 2004-01-13 WO PCT/US2004/000789 patent/WO2004071468A2/en active Search and Examination
- 2004-01-13 CA CA002512934A patent/CA2512934A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/877,767 patent/US7851454B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007531510A5 (ja) | ||
Meurens et al. | The pig: a model for human infectious diseases | |
Hansson et al. | Effect of local anaesthesia and/or analgesia on pain responses induced by piglet castration | |
JP2009544279A5 (ja) | ||
UA103298C2 (ru) | Способ лечения молодых свиней с помощью антигена pcv2 | |
EA200601603A1 (ru) | Миметические антитела glp-1 человека, композиции, способы и применения | |
Wang et al. | Morphology and chronology of diphyodont dentition in miniature pigs, Sus Scrofa | |
JP2012505837A5 (ja) | ||
JP2009537507A5 (ja) | ||
Cronin et al. | The effects of farrowing nest size and width on sow and piglet behaviour and piglet survival | |
JP2009538344A5 (ja) | ||
CN104885956A (zh) | 母猪定位栏 | |
Bechert et al. | Fertility control options for management of free-roaming horse populations | |
JP2005527226A5 (ja) | ||
TWI235666B (en) | Immunogenic LHRH compositions | |
Blackshaw | Prostaglandin F2a induced nest building behavior in the non-pregnant sow, and some welfare considerations | |
Banga et al. | Cow urine and immunomodulation: An update on cowpathy | |
Jewgenow | Immune contraception in wildlife animals | |
Pagan et al. | Husbandry and breeding of Somali wild ass Equus africanus somalicus at Basel Zoo, Switzerland 1 | |
Johnson et al. | Mandibular osteosarcoma in a nutria (Myocastor coypus) | |
JP4629964B2 (ja) | ウシの消化器疾患治療剤 | |
Schmitt et al. | Alternatives to the Use of Nonhuman Primates in Regulatory Toxicology | |
Gulbrandsen et al. | The influence of housing system on voluntary activity of horses. | |
Mokopasetso | Modeling foot and mouth disease risk factors in Botswana | |
RU2093177C1 (ru) | Препарат "дина" для лечения и профилактики заболеваний млекопитающих, птиц и рептилий |